Biotech startup Arnatar raises $50m Series A round to build China presence
Founded in 2022, Arnatar specialises in antisense drug discovery and development.
Source: dealstreetasia.com
Stay updated with breaking news from Jifeng Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Founded in 2022, Arnatar specialises in antisense drug discovery and development.
Biointron's $72m Series B and another 21 deals have raised a combined $280m.
/PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of...